002030 達安基因
按盤價 
6.870 -0.760 (-9.961%)
6.870 -0.760 (-9.961%) | 2025/09 - 九個月 人民幣(K¥) | 與去年同期 比較 | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | ||
| 營業總收入 | 503,507 | -14.81% | 853,024 | 1,180,897 | 12,046,135 | 7,664,262 | |
| 減：營業總成本 | 720,644 | 3.57% | 1,058,065 | 1,133,441 | 5,191,468 | 3,600,398 | |
| 其中:營業成本 | 339,024 | -4.43% | 532,743 | 584,929 | 3,271,535 | 1,934,079 | |
| 財務費用 | (29,610) | -38.07% | (65,069) | (74,749) | (111,036) | (30,813) | |
| 資產減值損失 | (7,666) | 6,627.21% | (75,040) | (262,754) | (681,999) | (19,243) | |
| 公允價值變動收益 | 206,552 | -273.25% | (175,746) | 435,691 | 82,321 | (83,779) | |
| 投資收益 | (4,988) | -96.17% | (253,838) | (26,247) | 271,184 | 219,125 | |
| 其中：對聯營企業和合營企業的投資收益 | (32,793) | -77.40% | (271,331) | (46,101) | 129,360 | 164,859 | |
| 營業利潤 | (165,400) | -70.82% | (1,067,605) | 121,622 | 6,329,254 | 4,125,397 | |
| 利潤總額 | (169,573) | -70.14% | (1,071,163) | 113,536 | 6,318,937 | 4,120,081 | |
| 減：所得稅費用 | (18,798) | -71.68% | (132,051) | 41,804 | 891,378 | 501,595 | |
| 淨利潤 | (150,775) | -69.94% | (939,113) | 71,732 | 5,427,558 | 3,618,487 | |
| 減：非控股權益 | (9,270) | -861.01% | (13,943) | (32,928) | 15,217 | 300 | |
| 股東淨利潤 | (141,505) | -71.85% | (925,170) | 104,660 | 5,412,341 | 3,618,187 | |
市場價值指標 | |||||||
| 每股收益 (元) * | -0.100 | -72.22% | -0.660 | 0.070 | 3.857 | 2.578 | |
| 每股派息 (元) * | -- | -- | -- | 0.015 | 1.750 | 1.110 | |
| 每股淨資產 (元) * | 5.516 | -7.00% | 5.615 | 6.327 | 8.052 | 5.238 | |
| 審計意見 # | -- | 标准的无保留意见 | 标准的无保留意见 | 标准的无保留意见 | 标准的无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 報價延遲最少15分鐘，資料更新時間為 29/01/2026 15:05 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
